Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON--(BUSINESS WIRE)-- Ensoma, an in vivo hematopoietic stem cell (HSC) ...
Remodeled the cold solid tumor microenvironment, marked by macrophage M1 polarization, increased lymphocyte recruitment, and production of inflammatory cytokines and chemokines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results